Skip to main content

Table 1 Patient demographics, postoperative treatment, and union time

From: Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy

Case Age (y) Sex Side Fracture mechanism Fracture location Duration of ALN therapy (m) BMD (T-score) Surgery Postoperative treatment Union time (m)
1 84 F R Sprain FS 36 −2.4 IMN ALN 24
    L* Sprain FS 62 NA IMN ALN 31
2 88 F R Slipping fall FS 94 −2.8 IMN ALN 20
3 80 F R Sprain FS 65 −4.2 IMN ALN 18
    L* Sprain FS 112 NA IMN ALN 18
4 83 F R Slipping fall FS 50 −1.0 IMN ALN 30
5 77 F L Sprain FS 63 −3.0 IMN TPTD 5
    R** Sprain FS 63 NA IMN SR 4
6 78 F R Slipping fall FS 52 −1.8 IMN SR 4
7 74 F R Slipping fall ST 64 −1.7 CMN SR 5
  1. ALN, alendronate; BMD, bone mineral density; FS, femoral shaft; ST, subtrochanteric; NA, not available; IMN, intramedullary nail; CMN, cephalomedullary nail; TPTD, teriparatide; SR, strontium ranelate.
  2. *Sequential contralateral fractures occurred in the patient continued alendronate after surgery.
  3. **Discontinued bone-forming agent after union of the initial fracture, and sequential contralateral femoral fracture noted 24 months later.